Fangxian Sun

4.4k total citations
21 papers, 1.3k citations indexed

About

Fangxian Sun is a scholar working on Oncology, Molecular Biology and Biotechnology. According to data from OpenAlex, Fangxian Sun has authored 21 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Biotechnology. Recurrent topics in Fangxian Sun's work include Cancer Research and Treatments (6 papers), Nanoplatforms for cancer theranostics (4 papers) and Cancer Mechanisms and Therapy (3 papers). Fangxian Sun is often cited by papers focused on Cancer Research and Treatments (6 papers), Nanoplatforms for cancer theranostics (4 papers) and Cancer Mechanisms and Therapy (3 papers). Fangxian Sun collaborates with scholars based in United States, France and China. Fangxian Sun's co-authors include Robert M. Hoffman, Michael Bouvet, Meng Yang, Ping Jiang, Eugene Baranov, Sheldon Penman, A. R. Moossa, Lingna Li, Hiroshi Shimada and Takashi Chishima and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Fangxian Sun

20 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fangxian Sun United States 11 641 369 316 278 197 21 1.3k
Tatiana Beresten United States 13 518 0.8× 277 0.8× 162 0.5× 154 0.6× 382 1.9× 17 1.1k
Lauren D. Stegman United States 12 512 0.8× 220 0.6× 141 0.4× 197 0.7× 257 1.3× 14 1.2k
Shahriar Yaghoubi United States 18 544 0.8× 625 1.7× 93 0.3× 343 1.2× 417 2.1× 30 1.6k
Franck Assayag France 17 549 0.9× 668 1.8× 155 0.5× 227 0.8× 108 0.5× 35 1.3k
Yoko S. DeRose United States 9 439 0.7× 699 1.9× 172 0.5× 165 0.6× 98 0.5× 10 1.1k
Vazgen Khankaldyyan United States 15 514 0.8× 243 0.7× 80 0.3× 188 0.7× 82 0.4× 21 1.1k
Paul F.J.W. Rijken Netherlands 24 502 0.8× 206 0.6× 117 0.4× 226 0.8× 130 0.7× 40 1.5k
Olav Engebraaten Norway 29 1.3k 2.1× 925 2.5× 150 0.5× 230 0.8× 149 0.8× 87 2.7k
Marc Damelin United States 17 1.2k 1.9× 738 2.0× 79 0.3× 119 0.4× 129 0.7× 39 1.9k
Luca Persano Italy 26 1.1k 1.8× 591 1.6× 86 0.3× 211 0.8× 81 0.4× 55 2.0k

Countries citing papers authored by Fangxian Sun

Since Specialization
Citations

This map shows the geographic impact of Fangxian Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fangxian Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fangxian Sun more than expected).

Fields of papers citing papers by Fangxian Sun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fangxian Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fangxian Sun. The network helps show where Fangxian Sun may publish in the future.

Co-authorship network of co-authors of Fangxian Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Fangxian Sun. A scholar is included among the top collaborators of Fangxian Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fangxian Sun. Fangxian Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shomali, Maysoun, Zhuyan Guo, Jane Cheng, et al.. (2022). Abstract P4-02-08: Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER+ endocrine-resistant breast cancer xenograft models. Cancer Research. 82(4_Supplement). P4–2. 2 indexed citations
2.
Tolstykh, Tatiana, Yuan Zhang, Dinesh S. Bangari, et al.. (2021). An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy. OncoImmunology. 10(1). 1881268–1881268. 20 indexed citations
3.
Shomali, Maysoun, Fangxian Sun, Laurent Besret, et al.. (2021). Abstract 739: Preclinical and clinical activity of SAR439859, Amcenestrant, a next generation SERD. Cancer Research. 81(13_Supplement). 739–739.
4.
Gregory, Richard C., Rita Greco, Hongjing Qu, et al.. (2018). Abstract 2790: The anti-TGFβ neutralizing antibody, SAR439459, blocks the immunosuppressive effects of TGFβ and inhibits the growth of syngeneic tumors in combination with anti-PD1. Cancer Research. 78(13_Supplement). 2790–2790. 3 indexed citations
5.
Theilhaber, Joachim, Stephen F. Madden, Sherry Cao, et al.. (2018). Abstract 5550: Translational biomarkers for SAR439459, an anti-TGFβ antibody for cancer immunotherapy. Cancer Research. 78(13_Supplement). 5550–5550. 1 indexed citations
6.
Dai, Cheng, Jun Liu, Dong Han, et al.. (2016). Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors. ACS Medicinal Chemistry Letters. 7(7). 676–680. 44 indexed citations
7.
Wang, Anlai, Rita Greco, Zhifang Li, et al.. (2014). Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms. Oncotarget. 5(10). 3362–3374. 24 indexed citations
8.
Moreira, Dayson, Sumanta K. Pal, Fangxian Sun, & Marcin Kortylewski. (2014). The effect of selective JAK2 inhibitor SAR302503 on tumorigenic STAT3 signaling in human prostate cancer in vivo.. Journal of Clinical Oncology. 32(4_suppl). 192–192. 1 indexed citations
9.
Greco, Rita, Fangxian Sun, Anlai Wang, et al.. (2013). Abstract 2435: Anticipating clinical resistance to SAR302503, a JAK2 inhibitor in clinical development for the treatment of myelofibrosis.. Cancer Research. 73(8_Supplement). 2435–2435. 1 indexed citations
10.
Greco, Rita, Fangxian Sun, Qunyan Yu, et al.. (2012). Abstract 1796: SAR302503: A Jak2 inhibitor with antitumor activity in solid tumor models. Cancer Research. 72(8_Supplement). 1796–1796. 4 indexed citations
11.
Choi, Hwan Geun, Pingda Ren, Francisco Adrián, et al.. (2010). A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl. Journal of Medicinal Chemistry. 53(15). 5439–5448. 58 indexed citations
12.
Gumireddy, Kiranmai, Fangxian Sun, Andres J. Klein–Szanto, et al.. (2007). In vivo selection for metastasis promoting genes in the mouse. Proceedings of the National Academy of Sciences. 104(16). 6696–6701. 69 indexed citations
13.
Galkin, Anna, Sung Joon Kim, Tami Hood, et al.. (2006). Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proceedings of the National Academy of Sciences. 104(1). 270–275. 289 indexed citations
14.
Wang, Jinwei, Meng Yang, Xiaoen Wang, et al.. (2003). Antimetastatic efficacy of oral 5-FU imaged by green fluorescent protein in real time.. PubMed. 23(1A). 1–6. 7 indexed citations
15.
Sun, Fangxian, Akiko Tohgo, Michael Bouvet, et al.. (2003). Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model.. PubMed. 63(1). 80–5. 50 indexed citations
16.
Li, Xiaoming, Jinwei Wang, Zili An, et al.. (2002). Optically imageable metastatic model of human breast cancer. Clinical & Experimental Metastasis. 19(4). 347–350. 39 indexed citations
17.
Yang, Meng, Eugene Baranov, Jinwei Wang, et al.. (2002). Direct external imaging of nascent cancer, tumor progression, angiogenesis, and metastasis on internal organs in the fluorescent orthotopic model. Proceedings of the National Academy of Sciences. 99(6). 3824–3829. 150 indexed citations
18.
An, Zili, Fangxian Sun, Xiaoming Li, et al.. (2000). Efficacy of intra-hepatectomy 5-FU on recurrence and metastasis of human hepatocellular carcinoma in nude mice. International Journal of Cancer. 91(2). 231–235. 2 indexed citations
19.
Yang, Meng, Eugene Baranov, Ping Jiang, et al.. (2000). Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proceedings of the National Academy of Sciences. 97(3). 1206–1211. 419 indexed citations
20.
Xia, Jinglin, et al.. (1997). Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology. 123(7). 383–387. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tatiana Beresten Breakdown of academic impact, for papers by Lauren D. Stegman Breakdown of academic impact, for papers by Shahriar Yaghoubi Breakdown of academic impact, for papers by Franck Assayag Breakdown of academic impact, for papers by Yoko S. DeRose Breakdown of academic impact, for papers by Vazgen Khankaldyyan Breakdown of academic impact, for papers by Paul F.J.W. Rijken Breakdown of academic impact, for papers by Olav Engebraaten Breakdown of academic impact, for papers by Marc Damelin Breakdown of academic impact, for papers by Luca Persano
Rankless by CCL
2026